Prothrombin Complex Concentrate (PCC) for Non-Vitamin K Oral Anticoagulant (NOAC) reversal: Good enough for now?
J Thromb Haemost. 2014 Jul 14;
Authors: Makris M
Abstract
Vitamin K antagonists have been the main oral anticoagulants in use worldwide for more than 50 years. They are highly effect in preventing recurrence of venous thromboembolism and thrombotic stroke in patients with atrial fibrillation (1, 2). Despite this high degree of efficacy they have a number of limitations including need for regular monitoring, significant interactions with multiple medications, and are associated with bleeding complications. The overall risk of bleeding on warfarin has been reported to be 3.0% annually for serious and 0.6% for fatal bleeding (3). This article is protected by copyright. All rights reserved.
PMID: 25039898 [PubMed - as supplied by publisher]